Filing summary
Entity and period: The filing is for Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-Q for the quarter ended September 30, 2020—Organovo’s fiscal second quarter of fiscal 2021—not 2020 Q2. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless otherwise noted.
Business context and reporting period
Organovo is an early-stage biotechnology company developing 3D human tissues and disease models for drug discovery and development. After suspending its prior therapeutic tissue programs in August 2019 and pursuing strategic alternatives, it recommenced operations following the September 2020 annual meeting and shifted its focus toward discovering and developing drug candidates using its 3D tissue platform. The proposed merger with Tarveda Therapeutics was not approved by stockholders and was terminated.
The company plans to build a research team, pursue internally directed or partnered drug discovery, and aims to begin human clinical testing for at least one drug candidate within three to five years. It also plans to seek a new San Diego office and laboratory facility.
Financial performance and liquidity
| Metric | Three months ended September 30, 2020 | Six months ended September 30, 2020 | Comparable 2019 period |
|---|---|---|---|
| Revenue | $0 | $0 | $1.23 million and $1.90 million, respectively |
| Research and development expense | $0.03 million | $0.03 million | $1.45 million and $5.27 million, respectively |
| Selling, general and administrative expense | $8.92 million | $11.71 million | $6.35 million and $9.66 million, respectively |
| Operating loss | $8.95 million | $11.74 million | $6.83 million and $13.35 million, respectively |
| Net loss | $8.95 million | $11.72 million | $6.29 million and $12.62 million, respectively |
| Cash used in operating activities | Not presented for the quarter | $9.72 million | $11.09 million for six months |
- Cash and cash equivalents were $17.66 million at September 30, 2020, down from $27.36 million at March 31, 2020. Working capital was $18.83 million, versus $26.51 million at March 31.
- Total assets were $20.64 million; current liabilities were $0.66 million. The filing reports no debt balance.
- Six-month cash declined by $9.70 million. Financing provided only $0.01 million in the period, compared with $4.94 million in the prior-year period, which included ATM offering proceeds.
- Margins are not meaningful because revenue was zero in the current periods.
- Accumulated deficit was $291.18 million. Six-month stock-based compensation expense was $5.06 million.
Material changes versus the prior comparable period
- Revenue ceased: no revenue was recorded in either current-period interval, following the prior restructuring and the end of revenue-generating activities. Prior-year revenue was $1.23 million for the quarter and $1.90 million for six months.
- Research and development expense fell sharply after activities were halted; management said it expects renewed R&D to increase expenses going forward.
- Quarterly SG&A rose 41% year over year and six-month SG&A rose 21%, mainly due to change-of-control-triggered severance and stock-based compensation.
- The quarter included $2.81 million of severance expense and a significant noncash compensation charge. The filing attributes approximately $3.5 million of one-time stock-based compensation and $2.8 million of severance to the change of control; total quarterly stock-based compensation was $4.14 million.
- On August 18, 2020, the company completed a 1-for-20 reverse stock split. Nasdaq notified the company on September 2 that it had regained minimum bid-price compliance.
- The September annual meeting resulted in new directors and the resignation of four directors, triggering change-of-control provisions. Approximately $2.8 million of severance and approximately $1.7 million net of returned premium for D&O tail insurance were among the disclosed one-time cash outlays; the company also reported a new D&O policy premium of approximately $0.8 million.
Outlook, risks, contingencies, and unusual items
- Management said cash on hand should cover financial obligations for at least the next 12 months under its current plan. It also said additional capital will be needed to implement the renewed drug-discovery plan; timing, amount, availability, and terms are uncertain. Financing could dilute shareholders or impose debt restrictions.
- The company expects substantial operating losses as R&D resumes and does not expect meaningful revenue in the foreseeable future. Its drug-discovery strategy is new and unproven; it has not identified drug candidates under the new model.
- Execution depends on hiring scientific staff, obtaining laboratory space and equipment, securing reliable human-cell supplies, and establishing partners. Management planned R&D staffing of seven to ten employees and G&A staffing of three to five.
- COVID-19 could disrupt supply chains, partners, research, and future development; management said it believed operations had not otherwise been negatively affected to date.
- Potential conflicts of interest involving Viscient Biosciences are disclosed: Organovo’s executive chairman and other personnel have roles at Viscient, and the companies may share employees, facilities, equipment, and intellectual property. The filing notes related-party activity and potential future dealings.
- An SEC inquiry into prior disclosures and related operations concluded on October 5, 2020; the SEC stated it did not intend to recommend an enforcement action against Organovo. A stockholder demand letter relating to merger disclosures was described as without merit and moot. The company recorded no accrual for legal contingencies.
- Management reported disclosure controls and procedures were effective at quarter-end and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the correct issuer and period: this is Organovo Holdings, Inc.’s quarter ended September 30, 2020, not a Vivosim Labs filing or 2020 Q2 period.
- Assess whether the stated 12-month cash runway remains credible after restarting R&D, hiring, and securing laboratory facilities—and whether new financing will be required sooner.
- Track cash burn, operating expenses, capital-raising capacity, potential dilution, and the availability and terms of financing.
- Monitor concrete milestones for the new drug-discovery strategy, including disease-model validation, candidate selection, partnerships, and progress toward the stated clinical-testing goal.
- Review the change-of-control costs and stock-based compensation charges, and clarify which costs are recurring versus one-time.
- Evaluate governance and related-party safeguards for dealings with Viscient, as well as the company’s ability to maintain Nasdaq listing compliance.